Resistant hypertension

Authors

  • Mario Bendersky Cátedra de Farmacología Aplicada. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba.

DOI:

https://doi.org/10.31053/1853.0605.v69.n3.21123

Keywords:

Hypertension

Abstract

Resistant hypertension, defined as a persistent blood pressure over 140/90 mmHg despite the use of three antihypertensive agents including a diuretic, is unusual. The diagnosis requires ruling out initially pseudoresistance and a deficient compliance with treatment. Ambulatory blood pressure recording allow the recognition of white coat hypertension. When there is a clinical or laboratory suspicion, secondary causes of hypertension should be discarded. Excessive salt intake, the presence of concomitant diseases such diabetes, chronic renal failure, obesity, and psychiatric conditions as panic attacks, anxiety and depression, should also be wanted. The presence of target organ damage requires a more aggressive treatment of hypertension. Recent clinical studies indicate that the administration of aldosterone antagonists as a fourth therapeutic line provides significant additional blood pressure reduction, when added to previous antihypertensive regimens in subjects with resistant hypertension.

Downloads

Download data is not yet available.

References

Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 108.189 Full Text

Pimenta E, Gaddam KK, Oparil S. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich). 2008 Mar;10(3):239-44 Full Text

Pimenta E; Calhoun DA ; Oparil S Mechanisms and treatment of resistant hypertension Arq. Bras. Cardiol. vol.88 no.6 , June 2007 Full text

Nishizaka MK, Zaman MA y Calhoun DA Efficacy of Low-Dose Spironolactone in Subjects with Resistant Hypertension American Journal of Hypertension 16(11):925-930, Nov 2003 PubMed

Marin M Aldosterona e hipertensión arterial. Boletín del Consejo Argentino de H.T.A. - Año 6 - Julio-Diciembre – 2005

de Souza F, Muxfeldt ES, Salles GF Prognostic factors in resistant hypertension: implications for cardiovascular risk stratification and therapeutic management. Expert Rev Cardiovasc Ther. 2012 Jun;10(6):735-45. PubMed

Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007 Apr;49(4):839-45 Full text

Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet. 2012 Aug 11;380(9841):591-600. PubMed

Gassler JP, Lynch PS, Bisognano JD The role of baroreflex activation therapy in sympathetic modulation for the treatment of resistant hypertension. Heart. 2012 Aug 15. PubMed

Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012 Sep;60(3):596-606 PubMed

Mancia, Giuseppe Additional drug treatment in resistant hypertension: need for randomized studies J Hypertens 2012,30:1514–1515 PubMed

Bobrie, Guillaume; Frank, Michael; Azizi, Michel; Peyrard, Séverine; Boutouyrie, Pierre; Chatellier, Gilles; Laurent, Stéphane; Menard, Joël; Plouin, Pierre-François Sequential nephron blockade versus sequential renin–angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study J Hypertension. 30(8):1656-1664, 2012. PubMed

Published

2012-09-04

How to Cite

1.
Bendersky M. Resistant hypertension. Rev Fac Cien Med Univ Nac Cordoba [Internet]. 2012 Sep. 4 [cited 2024 Jul. 6];69(3):156-9. Available from: https://revistas.unc.edu.ar/index.php/med/article/view/21123

Issue

Section

Literature Reviews